| # | Drug | Count |
|---|---|---|
| 0 | DUPILUMAB | 452 |
| 1 | TOCILIZUMAB | 401 |
| 2 | OMALIZUMAB | 283 |
| 3 | ALTEPLASE | 264 |
| 4 | INSULIN GLARGINE | 154 |
| 5 | BEVACIZUMAB | 120 |
| 6 | DORNASE ALFA | 118 |
| 7 | TIRZEPATIDE | 103 |
| 8 | OCRELIZUMAB | 101 |
| 9 | RITUXIMAB | 101 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND BACITRACIN ZINC | 1 | 0.0769 |
| 1 | SODIUM CHLORIDE FOR IRRIGATION | 1 | 0.0714 |
| 2 | RANIBIZUMAB-NUNA | 1 | 0.0213 |
| 3 | ADAPALENE AND BENZOYL PEROXIDE | 1 | 0.0185 |
| 4 | ALTEPLASE | 264 | 0.0176 |
| 5 | VITAMINS AND MINERALS | 1 | 0.0112 |
| 6 | HYPOCHLOROUS ACID | 1 | 0.0093 |
| 7 | FARICIMAB | 67 | 0.0076 |
| 8 | TENECTEPLASE | 11 | 0.0069 |
| 9 | DORNASE ALFA | 118 | 0.0060 |
| # | Drug class | Count |
|---|---|---|
| 0 | Interleukin-4 Receptor alpha Antagonist [EPC] | 452 |
| 1 | Interleukin-6 Receptor Antagonist [EPC] | 420 |
| 2 | Anti-IgE [EPC] | 283 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 246 |
| 4 | HER2/neu Receptor Antagonist [EPC] | 195 |
| 5 | Insulin Analog [EPC] | 172 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 171 |
| 7 | PCSK9 Inhibitor [EPC] | 137 |
| 8 | GLP-1 Receptor Agonist [EPC] | 125 |
| 9 | Recombinant Human Deoxyribonuclease 1 [EPC] | 118 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Endoglycosidase [EPC] | 66 | 0.0356 |
| 1 | Recombinant Human Deoxyribonuclease 1 [EPC] | 118 | 0.0060 |
| 2 | Interleukin-5 Antagonist [EPC] | 4 | 0.0058 |
| 3 | PCSK9 Inhibitor [EPC] | 137 | 0.0053 |
| 4 | Thyroid Stimulating Hormone [EPC] | 4 | 0.0039 |
| 5 | Anti-IgE [EPC] | 283 | 0.0032 |
| 6 | Interleukin-6 Receptor Antagonist [EPC] | 420 | 0.0030 |
| 7 | Guanylate Cyclase-C Agonist [EPC] | 6 | 0.0029 |
| 8 | Survival of Motor Neuron 2 Splicing Modifier [EPC] | 12 | 0.0029 |
| 9 | Ectoparasiticide [EPC] | 11 | 0.0028 |